Here you can find the latest resources related to CEPI:
- Priority diseases
- Summary review on vaccine regulatory pathways important for CEPI
- Preliminary Business Plan 2017-2021
CEPI will initially target the MERS-CoV, Lassa and Nipah viruses, which have known potential to cause serious epidemics. It aims to develop two promising vaccine candidates against each of these diseases, so these are available without delay if and when an outbreak begins.
CEPI took the WHO’s R&D Blueprint for Action to Prevent Epidemics as its starting point. This contains a list of priority pathogens against which medical countermeasures are urgently needed. CEPI’s Scientific Advisory Committee chose these three diseases based on a set of criteria including the public health impact, the risk of an outbreak occurring and the feasibility of vaccine development, based on current knowledge, tools and pipeline candidates.
More information about the priority diseases can be found here:
CEPI is collaborating with ProMED to provide up-to-date and reliable news about the CEPI priority diseases on the frontpage of the website.
Questionnaire guidance document
This is a document to support the completion of the “CEPI Questionnaire on regulatory science issues for development of emerging infectious disease (EID) vaccines”. Respondents have been sent a link to the questionnaire in their email.Download
Summary review on vaccine regulatory pathways important for CEPI
This summary review on vaccine regulatory pathways important for CEPI was initiated under Task Team 1, specifically the sub-groups looking at clinical development and regulatory affairs groups. The purpose of this summary is to provide an overview of the current regulatory standards available for EIDs in an emergency. This summary will be a reference for future work related to vaccine and regulatory pathways important for CEPI and an important tool to further engage and work with regulatory partners on collaborative efforts to provide advice and negotiate on regulatory and ethical pathways for vaccines for and during epidemics. A working group focused on regulatory affairs will develop a work plan and coordinate further work with the CEPI Scientific Advisory Committee (SAC) and Joint Coordination Group (JCG).Download
Appendix to the summary reviewDownload
Preliminary Business Plan 2017-2021
In the preliminary Business Plan for the period 2017 – 2021, CEPI commits to tackle the barriers to epidemic vaccine development, advancing safe, effective, and affordable vaccines to contain outbreaks at the earliest possible stage.
The focus is on two main objectives:
- Advancing at least four vaccine candidates against two to three priority pathogens to proof-of-concept in five years, to enable clinical efficacy testing in the initial stages of a potential outbreak;
- Building technical and institutional platforms to accelerate R&D response to known or unknown pathogen emergencies. CEPI is also exploring how to support multivalent Ebola vaccine R&D and facilitate regulatory preparedness and stockpiling.
CEPI will ensure sustainability of its partnership approach by: securing industry participation through partnerships that share the risks and benefits of vaccine development; and supporting the long-term development of regional capabilities for epidemic vaccine preparedness. The CEPI Business Plan builds on scoping, research and analysis facilitated by consultations with over 80 organizations and more than 200 individuals since February 2016. This is a preliminary version of the Business Plan for the period 2017-2021 which will be further refined and updated by end 2017.